229 related articles for article (PubMed ID: 16491401)
1. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides.
Hunger RE; Kernland Lang K; Markowski CJ; Trachsel S; Møller M; Eriksen JA; Rasmussen AM; Braathen LR; Gaudernack G
Cancer Immunol Immunother; 2011 Nov; 60(11):1553-64. PubMed ID: 21681371
[TBL] [Abstract][Full Text] [Related]
3. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
[TBL] [Abstract][Full Text] [Related]
4. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.
Bernhardt SL; Gjertsen MK; Trachsel S; Møller M; Eriksen JA; Meo M; Buanes T; Gaudernack G
Br J Cancer; 2006 Dec; 95(11):1474-82. PubMed ID: 17060934
[TBL] [Abstract][Full Text] [Related]
5. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
Greten TF; Forner A; Korangy F; N'Kontchou G; Barget N; Ayuso C; Ormandy LA; Manns MP; Beaugrand M; Bruix J
BMC Cancer; 2010 May; 10():209. PubMed ID: 20478057
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
7. Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.
Staff C; Mozaffari F; Frödin JE; Mellstedt H; Liljefors M
Int J Oncol; 2014 Sep; 45(3):1293-303. PubMed ID: 24919654
[TBL] [Abstract][Full Text] [Related]
8. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
10. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.
Shaw VE; Naisbitt DJ; Costello E; Greenhalf W; Park BK; Neoptolemos JP; Middleton GW
Expert Rev Vaccines; 2010 Sep; 9(9):1007-16. PubMed ID: 20822343
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Middleton G; Silcocks P; Cox T; Valle J; Wadsley J; Propper D; Coxon F; Ross P; Madhusudan S; Roques T; Cunningham D; Falk S; Wadd N; Harrison M; Corrie P; Iveson T; Robinson A; McAdam K; Eatock M; Evans J; Archer C; Hickish T; Garcia-Alonso A; Nicolson M; Steward W; Anthoney A; Greenhalf W; Shaw V; Costello E; Naisbitt D; Rawcliffe C; Nanson G; Neoptolemos J
Lancet Oncol; 2014 Jul; 15(8):829-40. PubMed ID: 24954781
[TBL] [Abstract][Full Text] [Related]
12. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.
Hansen GL; Gaudernack G; Brunsvig PF; Cvancarova M; Kyte JA
Cancer Immunol Immunother; 2015 Dec; 64(12):1609-21. PubMed ID: 26498005
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
[TBL] [Abstract][Full Text] [Related]
14. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
Kyte JA; Gaudernack G; Dueland S; Trachsel S; Julsrud L; Aamdal S
Clin Cancer Res; 2011 Jul; 17(13):4568-80. PubMed ID: 21586625
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccination with telomerase peptide GV1001.
Kyte JA
Expert Opin Investig Drugs; 2009 May; 18(5):687-94. PubMed ID: 19388882
[TBL] [Abstract][Full Text] [Related]
16. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Ellingsen EB; Aamdal E; Guren T; Lilleby W; Brunsvig PF; Mangsbo SM; Aamdal S; Hovig E; Mensali N; Gaudernack G; Inderberg EM
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35613827
[TBL] [Abstract][Full Text] [Related]
17. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma.
Mizukoshi E; Nakagawa H; Kitahara M; Yamashita T; Arai K; Sunagozaka H; Fushimi K; Kobayashi E; Kishi H; Muraguchi A; Kaneko S
Cancer Lett; 2015 Aug; 364(2):98-105. PubMed ID: 25982205
[TBL] [Abstract][Full Text] [Related]
18. Telomerase based anticancer immunotherapy and vaccines approaches.
Kailashiya C; Sharma HB; Kailashiya J
Vaccine; 2017 Oct; 35(43):5768-5775. PubMed ID: 28893481
[TBL] [Abstract][Full Text] [Related]
19. Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma.
Schlapbach C; Yerly D; Daubner B; Yawalkar N; Hunger RE
J Dermatol Sci; 2011 May; 62(2):75-83. PubMed ID: 21377838
[TBL] [Abstract][Full Text] [Related]
20. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O
Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
